Katharina Gruntz1, Marlene Bloechliger1, Claudia Becker1, Susan S Jick2,3, Peter Fuhr4, Christoph R Meier1,2,5, Stephan Rüegg4. 1. Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacy and Epidemiology, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland. 2. Boston Collaborative Drug Surveillance Program, Lexington, MA. 3. Boston University School of Public Health, Boston, MA. 4. Division of Clinical Neurophysiology, Department of Neurology, University Hospital Basel, Basel, Switzerland. 5. Hospital Pharmacy, University Hospital Basel, Basel, Switzerland.
Abstract
OBJECTIVE: To assess the association between incident Parkinson disease (PD) and subsequent incident epileptic seizures. METHODS: We conducted a retrospective cohort study with a nested case-control analysis using data from the U.K. Clinical Practice Research Datalink. We identified patients aged ≥40 years with an incident diagnosis of PD between 1995 and 2016 and a matched comparison group of PD-free individuals. We calculated crude incidence rates (IRs) with 95% confidence intervals (CIs) of epileptic seizures in PD patients and the PD-free comparison group, and corresponding crude incidence rate ratios (IRRs). In the nested case-control analysis, we calculated adjusted odds ratios (adj. ORs) of incident PD among cases with incident epileptic seizures and seizure-free controls overall and stratified by various seizure-provoking comorbidities. RESULTS: Among 23,086 incident PD patients and 92,343 PD-free individuals, we identified 898 patients with incident epileptic seizures. The crude IR of epileptic seizures in PD patients was 266.7/100,000 person-years (95% CI = 235.6-297.7), and in PD-free individuals it was 112.4/100,000 person-years (95% CI = 103.5-121.3; IRR = 2.37, 95% CI = 2.06-2.73). The adj. OR of epileptic seizures was 1.68 (95% CI = 1.43-1.98) in PD patients compared with PD-free individuals. PD patients with comorbid brain disorders (adj. OR = 12.36, 95% CI = 8.74-17.48) or with > 1 seizure-provoking comorbidity (adj. OR = 13.24, 95% CI = 10.15-17.25) were at the highest risk of epileptic seizures compared with PD-free individuals with no seizure-provoking comorbidities. INTERPRETATION: This study suggests that incident PD is associated with an increased risk of incident epileptic seizures. Ann Neurol 2018;83:363-374.
OBJECTIVE: To assess the association between incident Parkinson disease (PD) and subsequent incident epileptic seizures. METHODS: We conducted a retrospective cohort study with a nested case-control analysis using data from the U.K. Clinical Practice Research Datalink. We identified patients aged ≥40 years with an incident diagnosis of PD between 1995 and 2016 and a matched comparison group of PD-free individuals. We calculated crude incidence rates (IRs) with 95% confidence intervals (CIs) of epileptic seizures in PDpatients and the PD-free comparison group, and corresponding crude incidence rate ratios (IRRs). In the nested case-control analysis, we calculated adjusted odds ratios (adj. ORs) of incident PD among cases with incident epileptic seizures and seizure-free controls overall and stratified by various seizure-provoking comorbidities. RESULTS: Among 23,086 incident PDpatients and 92,343 PD-free individuals, we identified 898 patients with incident epileptic seizures. The crude IR of epileptic seizures in PDpatients was 266.7/100,000 person-years (95% CI = 235.6-297.7), and in PD-free individuals it was 112.4/100,000 person-years (95% CI = 103.5-121.3; IRR = 2.37, 95% CI = 2.06-2.73). The adj. OR of epileptic seizures was 1.68 (95% CI = 1.43-1.98) in PDpatients compared with PD-free individuals. PDpatients with comorbid brain disorders (adj. OR = 12.36, 95% CI = 8.74-17.48) or with > 1 seizure-provoking comorbidity (adj. OR = 13.24, 95% CI = 10.15-17.25) were at the highest risk of epileptic seizures compared with PD-free individuals with no seizure-provoking comorbidities. INTERPRETATION: This study suggests that incident PD is associated with an increased risk of incident epileptic seizures. Ann Neurol 2018;83:363-374.
Authors: Chia-Hsuan Fu; Daniel Maxim Iascone; Iraklis Petrof; Anupam Hazra; Xiaohong Zhang; Mark S Pyfer; Umberto Tosi; Brian F Corbett; Jingli Cai; Jason Lee; Jin Park; Lorraine Iacovitti; Helen E Scharfman; Grigori Enikolopov; Jeannie Chin Journal: Cell Rep Date: 2019-06-25 Impact factor: 9.423
Authors: Nicol G M Oonk; Kris L L Movig; Job van der Palen; Henk-Willem Nijmeijer; Mirjam E van Kesteren; Lucille D A Dorresteijn Journal: Clin Drug Investig Date: 2021-08-10 Impact factor: 2.859
Authors: Xinshi Wang; Samantha M Loi; Emma Foster; Zhibin Chen; Dennis Velakoulis; Patrick Kwan Journal: Front Aging Neurosci Date: 2021-03-16 Impact factor: 5.750
Authors: Simote T Foliaki; Benjamin Schwarz; Bradley R Groveman; Ryan O Walters; Natalia C Ferreira; Christina D Orrù; Anna Smith; Aleksandar Wood; Olivia M Schmit; Phoebe Freitag; Jue Yuan; Wenquan Zou; Catharine M Bosio; James A Carroll; Cathryn L Haigh Journal: Mol Brain Date: 2021-10-11 Impact factor: 4.041
Authors: Emily L Johnson; Gregory L Krauss; Anna Kucharska-Newton; Alice D Lam; Rani Sarkis; Rebecca F Gottesman Journal: Neurology Date: 2021-07-19 Impact factor: 11.800